Latest News about ESALY
Recent news which mentions ESALY
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
June 12, 2023
From Benzinga
From Benzinga
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
June 08, 2023
From Benzinga
From Benzinga
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
June 08, 2023
From Benzinga
From Benzinga
From Benzinga
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
May 04, 2023
From Benzinga
From Benzinga
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
April 10, 2023
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From InvestorPlace
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
March 16, 2023
From Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
March 14, 2023
From Benzinga
From Benzinga
Why Anavex Life Sciences Stock Bolted Higher in January
February 08, 2023
From Motley Fool
From Benzinga
From Motley Fool
From Motley Fool
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
January 17, 2023
From Motley Fool
From Motley Fool
Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill
January 07, 2023
From Benzinga
FDA approves treatment for people with mild forms of Alzheimer’s
January 06, 2023
From MarketWatch
From Benzinga
Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock?
January 06, 2023
From InvestorPlace
1 Stock Defying the Downturn to Buy, and 1 to Avoid
January 06, 2023
From Motley Fool
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
From Benzinga
1 Green Flag and 1 Red Flag for Biogen
December 23, 2022
From Motley Fool